GLMN antibody targets the glomulin (GLMN) protein, a key regulator implicated in vascular development and tumor suppression. Initially identified through studies on glomuvenous malformations (GVMs), GLMN mutations are linked to familial forms of these vascular lesions. The protein interacts with the FKB12-rapamycin complex (mTORC1), modulating cellular growth and angiogenesis. GLMN's role extends to maintaining vascular integrity by regulating smooth muscle cell differentiation and endothelial function. Antibodies against GLMN are primarily used in research to investigate its expression patterns, subcellular localization, and mechanistic contributions to vascular pathologies. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Recent studies also explore GLMN's involvement in cancer, particularly in tumors with dysregulated mTOR signaling. The development of GLMN-specific antibodies has facilitated the identification of its binding partners and downstream effectors, offering insights into potential therapeutic strategies for vascular anomalies and mTOR-related malignancies. Despite progress, the precise molecular pathways governed by GLMN remain under investigation, highlighting the need for further antibody-based research to clarify its multifaceted biological roles.